Speed up the process and cut the cost of finding new treatments for Chagas disease and leishmaniasis by bringing together pharmaceutical companies in a multilateral, simultaneous, and non-competitive search process
current phase of drug development
updated 29 Feb 2020
The Drug Discovery Booster was launched in 2015 to circumvent early-stage commercial barriers between pharmaceutical participants, allowing DNDi to search millions of unique compounds simultaneously, using computational approaches to refine the search iteratively, in the hunt for new treatment leads.
‘This experiment could significantly reduce the time and money it takes to find new, promising treatment leads, and echoes the great potential of innovative research and development collaborations.’Dr Bernard Pécoul, Executive Director, DNDi
The innovation of the Drug Discovery Booster not only lies in the multilateral approach, but also in the iterative nature of the search, meaning companies will continually examine their libraries for better matches as the search is refined. This will significantly condense down the time it will take to find new, promising treatment leads.
The GHIT Fund, launched in 2013, stimulates and supports such international global health research and development partnerships. Through an initial grant of EUR 640,000/ 79.5 million Japanese Yen, a second grant of EUR 470,000/ 55 million Japanese Yen, and a third grant of EUR 1.2 million/ 158 million Japanese Yen provided to DNDi, GHIT will support the involvement of the four Japanese companies in this project.
‘IPK joined DNDi’s new initiative, the NTD Drug Discovery Booster programme, that cuts the cost of early-stage drug discovery, accelerates and expands discovery of new drugs for NTDs. In 2016, we identified four hit series that are currently advancing to further development. It is our hope that we can soon identify a breakthrough compound for patients.’David Shum, Group Leader, Assay Development & Screening, Institut Pasteur Korea, South Korea
News & press releases
- 27 July 2020 – Five years of the Neglected Tropical Diseases (NTD) Drug Discovery Booster
- 29 March 2018- DNDi welcomes Astellas to the NTD Drug Discovery Booster
- 18 April 2017 – Merck joins DNDi’s ‘Drug Discovery Booster’ to accelerate discovery of new treatments for neglected diseases
- 15 June 2016 – Celgene joins DNDi’s ‘Drug Discovery Booster’ to accelerate discovery of new treatments for neglected diseases
- 3 August 2015 – Al Jazeera The Cure “Finding a cure for Kala-azar” Click here to watch video
- 30 July 2015 – BioCentury “Neglected attention” Click here to access the article / PDF
- 1 June 2015 – The New York Times “Japanese companies attack neglected diseases” Click here to read the article
- 28 May 2015 – DNDi and four pharmaceutical companies announce ‘Drug Discovery Booster’ experiment
- Collaborative virtual screening to elaborate an imidazo[1,2-a]pyridine hit series for visceral leishmaniasis, RSC Medicinal Chemistry January 2021
NTD Drug Discovery Booster
Get our latest news, personal stories, research articles, and job opportunities.